Needham Reiterates Buy on Revolution Medicines, Maintains $61 Price Target

Benzinga · 10/25/2024 19:53
Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $61 price target.